Back
Treatment of early-morning hyperglycemia in type 1 diabetics with amorphous zinc insulin (Semilente) at bedtime.
Journal article

Treatment of early-morning hyperglycemia in type 1 diabetics with amorphous zinc insulin (Semilente) at bedtime.

  • 1993-01-01
Published in:
  • Hormone research. - 1993
Adult
Blood Glucose
Diabetes Mellitus, Type 1
Double-Blind Method
Drug Administration Schedule
Fasting
Female
Humans
Hyperglycemia
Insulin
Insulin, Long-Acting
Male
Middle Aged
Time Factors
English Fasting hyperglycemia in insulin-dependent diabetic patients (IDDM) treated according to the basal-bolus principle may be due to the fact that currently available neutral protamine Hagedorn (NPH) insulin preparations do not sufficiently meet the increased insulin need in the second part of the night. In the present study, it was investigated whether the amorphous zinc insulin Semilente can be used to control fasting hyperglycemia in IDDM patients. Ten type 1 diabetic patients with persistent fasting hyperglycemia (> 10 mmol/l) participated in the double-blind randomized cross-over trial with 2 10-day treatment periods. Night profiles of blood glucose and free insulin concentrations were determined at the end of each treatment period. Three doses of regular insulin were given before the meals and NPH insulin and Semilente at 10.00 p.m. Nighttime blood glucose and insulin profiles were different under the treatment with Semilente and NPH insulin. Injection of Semilente at bedtime resulted in higher insulin and lower blood glucose values during the second part of the night (p < 0.001 versus Semilente by ANOVA). Semilente injected at bedtime can prevent the early-morning rise in blood glucose in type I diabetic patients.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/4549
Statistics
Document views: 24 File downloads: